Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.
Resolian is committed to reducing its environmental impact wherever feasibly possible.
Recently the Extractables and Leachables team at the Fordham lab of Analytical Sciences aimed to implement and evaluate green chemistry principles.
In this visual podcast we explore why Australia is an attractive destination for early-phase clinical trials, highlighting the benefits of speed, quality, and cost-effectiveness.
The expert panel discussion delves into Australia’s unique regulatory pathways, the R&D tax incentives, operational logistics, and how early-phase data supports global drug development.
Titanium dioxide (TiO2) has been a critical excipient in pharmaceuticals for decades, offering exceptional opacity, whiteness, and stability. However, evolving regulatory demands are driving the industry to explore alternatives. Resolian provides advanced analytical and characterization support to guide this transition while ensuring product quality and compliance.
Our Flow Cytometry team have designed a sample processing package that solves the logisitcally challenges with samples.
In a globalized life sciences industry, maintaining consistent quality standards across multiple international sites is a major challenge.
Copyright © 2024 Resolian Inc. All rights reserved.
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.